INTRODUCTION
Nonsyndromic clefts of the lip and palate (NSCLP) are complex genetic traits and together, they are classified as one of the most common birth defect with a prevalence of 1/700 live birth [Mossey and Modell, 2012] . These defects are easily recognizable, responsive to surgical correction and benefit from substantial multi-disciplinary team care. This team care will help restore aesthetics, function, and psychosocial stability. However, this comes at a significant lifetime cost to the healthcare system and families [Wehby and Cassell, 2010] . The etiology of these complex traits has been widely studied in order for us to understand the risk factors and to design strategies for prevention. Genetic factors, environmental factors, and the interaction between these two factors have been extensively reported in the literature as prime contributors to cleft outcomes [Dixon et al., 2011] .
Genome-wide association studies for nonsyndromic cleft lip with or without palate (NSCL[P]) reported significant association for common variants in intergenic regions close to genes that are involved in craniofacial development i.e., MAFB, VAX1, PAX7, and IRF6 [Birnbaum et al., 2009; Grant et al., 2009; Beaty et al., 2010; Mangold et al., 2010] . A significant association was also reported in a gene desert in the Chr 8q.24 locus [Birnbaum et al., 2009; Grant et al., 2009; Beaty et al., 2010; Mangold et al., 2010] . This gene desert is enriched for epigenetic markers [Huppi et al., 2012] . A recent meta-analysis by Ludwig et al. [2012] confirmed previous GWAS findings and identified six new additional loci that are genome-wide significant. Additional studies in independent populations replicated the GWAS findings [Nikopensius et al., 2010; Rojas-Martinez et al., 2010; Fontoura et al., 2012; Butali et al., 2013] .
Resequencing studies conducted on the NSCL[P] GWAS candidate genes or adjacent genes suggest a role for rare variants [Beaty et al., 2010; Nasser et al., 2012; Butali et al., 2013] . Data on European and Asian cleft triads from the Beaty et al., [2010] GWAS study suggest that some genes/loci are population specific (chr8q24.21 for Europeans and MAFB for Asians), while other genes play a role in multiple populations (IRF6 in Europeans and Asians). This conforms to reports from recent population genetics studies showing rare variants to be population specific [Keinan and Clark, 2012; Tennessen et al., 2012] .
GWAS replication studies using samples in the African population did not observe any significant association with the GWAS candidate genes [Butali et al., 2011; Weatherley-White et al., 2011] . Nonetheless, the role of rare functional variants in GWAS candidate genes has not been evaluated in the African population. We obtained saliva samples from case triads in Nigeria and Ethiopia for Sanger sequencing of the GWAS candidate genes in order to potential etiologic rare variants.
MATERIALS AND METHODS Samples
The samples used for this genetic study were obtained in Nigeria and Ethiopia following ethical approval by the Institutional Review Boards at the Lagos University Teaching Hospital Idi-Araba, Lagos [IRB approval number: ADM/DCST/HREC/VOL.XV/321], Obafemi Awolowo University Teaching Hospital Ile-Ife (IRB approval number: ERC/2011/12/01), and the Addis Ababa University (IRB approval number: 003/10/surg). A signed informed consent was obtained from every family recruited after they had read the study information and personal discussions with a member of the research team at the cleft clinic. All patients were examined by maxillofacial surgeons in Nigeria and plastic surgeons in Ethiopia for the presence of other congenital anomalies, features of syndromic forms of clefts, and other major structural anomalies and were excluded if these were present [described in Butali et al., 2011] . We collected samples from 220 affected probands (191non-syndromic cleft lip with or without cleft palate (NSCL[P]) and 29 nonsyndromic cleft palate (NSC[P]) and both parents (where possible). In total, samples were collected from 50 complete triads and 170 dyads (these include 47 triads and 93 dyads from Nigeria and 3 triads and 77 dyads from Ethiopia).
The Oragene collection kit [www.dnagenotek.com] was used to collect saliva samples from adults and children who were able to spit into the tube. For the newborn and children who were unable to spit, we used saliva sponges to soak saliva sublingually or in the buccal sulcus and these sponges were cut into the Oragene collection tubes. Blood samples were also collected during surgery for all affected probands.
Samples were shipped to the US for downstream applications that include DNA processing and sequencing. The protocol for DNA processing can be accessed via the Murray Lab website [genetics@uiowa.edu]. We measured the DNA concentration for all the samples using Qubit [http://www.invitrogen.com/site/us/ en/home/brands/Product-Brand/Qubit.html] and a 4 ng/ul DNA concentration was used for Sanger sequencing.
Sequencing
We selected the genes identified from the GWAS reported by Beaty et al. [2010] . These include MAFB, PAX7, VAX1, ARHGAP29 (ABCA4 locus), and IRF6. We included ARHGAP29 reported by which was identified as the candidate gene following resequencing of the GWAS signal around the ABCA4. The method used for sequencing has been previously reported Butali et al., 2013] . In summary, primers for the coding regions of all the candidate genes (MAFB NM_00546; PAX7 NM_001135254.1; VAX1 NM_001112704.1; ARHGAP29 NM_004815.3; and IRF6 NM_006147.2) were designed using Primer 3 (http://bioinfo.ut.ee/primer3-0.4.0/) and optimized in the Murray lab using a gradient Polymerase Chain Reaction (PCR) to determine the annealing temperature for each primer set. A master mix containing 10xNH4 buffer, 5% DMSO, 200 mM DNTPs, 50 mM MgCl, water, 20 mM of forward and reverse primers and the 5u/ml Taq polymerase enzyme was prepared. We added 9 ml of the master mix to 1 ml of DNA in a 96-well plate. Two Centre d'Etude du Polymorphisme Humain (CEPH) samples and two water samples were added as controls. The primers used and annealing temperatures are available on request. Amplified DNA products were shipped to Functional Biosciences (http://order.functionalbio.com/seq/index) in Wisconsin for sequencing using an ABI 3730XL. Chromatograms were transferred to a Unix workstation, base-called with PHRED (v.0.961028), assembled with PHRAP (v. 0.960731), scanned by POLYPHRED (v. 0.970312), and viewed with the CONSED program (v. 4). Variants found were compared to the variants that are present in the 1000 genome (1 KG) database (http://www.1000genomes.org/) and the Exome Variant Server (EVS) database (http://snp.gs.washington.edu/EVS/). We predicted the functional effects of these variants on the protein by using bioinformatics tools, such as polyphen (http://genetics.bwh. harvard.edu/pph2/) [Adzhubei et al., 2010] , SIFT (http://sift.jcvi. org/) [Kumar et al., 2009] and HOPE (http://www.cmbi.ru.nl/ hope) [Venselaar et al., 2010] , and the Human Splice Finder (HSF) [Desmet et al., 2009] . We first sequenced only the probands in order to identify rare functional variants. In probands with new rare functional variants, we sequenced samples from their parents to tease out variants that are de novo or segregating in the family.
RESULTS

Sequencing Results
We found three new variants; a missense variant c.493C > G in MAFB, c.1282G > A in PAX7, and a splice-site variant c.952 þ 2T > A that changes the donor site in exon 5 of PAX7. Two new variants were also found: c.493C > G in one unaffected parent and c.952 þ 2T > A in another unaffected parent. For the proband with the c.1282G > A variant, we only have a sample from the father (who did not have the variant) and cannot confirm if the variant segregates or not. The other variants c.2864G > A and c.2738C > A in ARH-GAP29 and c.1396G > A in PAX7 have been previously identified. We did not identify any rare variant in VAX1.
The mutant residue (Serine) is bigger than the wild-type residue (Glycine) at position 466 of the PAX7 protein ( Fig. 1) and will probably not the fit core of the protein occupied by the wild type. Though the glycine residue is conserved at this position, a few other residue types have been observed at this position too. This includes the mutant Serine residue. This mutation is possibly not damaging to the protein based on conservation since homologous proteins exist with the same residue type as Serine mutant at this position.
The wild-type residue (Aspartic acid) is negatively charged and the mutant residue (Asparagine) is neutral at position 428 of the PAX7 protein (Fig. 2) . The negative charge of the buried wild-type residue in the core domain is lost when replaced by neutral mutation. The loss of negative charge might disturb the core structure of this domain.
The wild-type residue (Histidine) is not conserved at position 165 of the MAFB protein (Fig. 3) . The mutant residue (Asparagine) is among the observed residue types at this position in other homologous sequences. This suggests that this variant is not damaging to the protein's structure and function.
DISCUSSION
We found three new variants (p.Asp428Asn in PAX7; p.His165Asn in MAFB, and a donor splice site mutation in PAX7) following resequencing of GWAS candidate genes in the African population. The wild-type residue (Aspartic acid) in the variant p.Asp428Asn in PAX7 is highly conserved. Nonetheless, other residue types have been identified at this position too in homologous sequences. Neither the Asparagine residue nor another residue with similar properties was observed at this position in other homologous sequences. Therefore, based on conservation scores and amino acid properties, the variant in PAX7 was predicted to be probably damaging and deleterious. Glycine, the wild-type residue in the variant p.Gly466Ser in PAX7, is the most flexible of all residues and this unique property might be necessary for the protein's function. This flexibility may be required at this position to make a greater supporting structure or to ease movement of the protein. Therefore, mutation of glycine can eliminate these molecular properties by affecting the structure and movement of the protein leading to a less flexible residue. We previously reported this mutation in a Filipino case with CLP [Butali et al., 2013] .
The variant p.His165Asn in MAFB was predicted to be benign by polyphen (http://genetics.bwh.harvard.edu/pph2/) [Adzhubei et al., 2010] and tolerated by SIFT (http://sift.jcvi.org/) [Kumar et al., 2009] . HOPE (http://www.cmbi.ru.nl/hope) [Venselaar et al., 2010] shows that the mutant residue is smaller than the wild type and this change in size can be detrimental to the molecular interactions and deleterious to the protein. A previous study reported a rare damaging variant at position p.His131Glu in a Filipino case [Beaty et al., 2010] . The variants in ARHGAP29 are known variants and previously reported in NSCL[P] by . The ARHGAP29 variants were also found in the 1000 genome database and Exome Variant Server (EVS). The individuals in the 1000 genome database have limited clinical information and family history; and the individuals in the Exome Variant Server were selected for specific heart, lung, and blood diseases. Therefore, it is possible that these variants may be rare normal variants, but because the cleft status of individuals in the EVS database is unknown, we cannot be sure. There are Nigerians and Kenyans (from East Africa -sharing the same border and similar geographical location as Ethiopia) in the 1 KG database. In the EVS, there are African Americans who are historically from West Africa (the geographical region where Nigeria is). Individuals in both databases serve as population controls for our cases. We observed that two of the new mutations [c.493C > G and c.952 þ 2T > A] are in unaffected parents suggesting that there is incomplete penetrance of the phenotype in these individuals.
Previous studies have argued that it is important to investigate diverse populations in the study of complex diseases [Ramos et al., 2012] . A recent GWAS clearly showed the existence of population heterogeneity for some candidate genes [Beaty et al., 2010] . In addition, rare coding variants have been reported to play a role in the etiology of NSCLP . The data on the new rare variants in PAX7 and MAFB (conservation score, amino acid properties and disruption of core domain) in the cases and not in controls suggest they are etiologic and specific to the African population. Our study thus provides additional evidence that studies in diverse populations may identify rare variants that are population specific.
The etiology of NSCL[P] is complex and it is possible that there are new candidate genes that may be specific to the African population -but this requires further verification. The findings also support the notion that rare variants may be populationspecific or individual family specific. Therefore, future genomewide studies in an independent African population should be conducted in order to unravel these additional molecular genetic etiologies in addition to considering the role of common and unique environmental etiologies as co-variate in NSCLP risk. 
